- Home
- ROIV vs CRDO Comparison
ROIV vs CRDO Comparison
Compare ROIV & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CRDO |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United Kingdom | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 20.3B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CRDO |
|---|---|---|
| Price | $27.43 | $103.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $27.56 | ★ $176.36 |
| AVG Volume (30 Days) | 4.4M | ★ 5.8M |
| Earning Date | 02-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 261.11 |
| EPS | N/A | ★ 1.62 |
| Revenue | $29,053,000.00 | ★ $436,775,000.00 |
| Revenue This Year | N/A | $210.92 |
| Revenue Next Year | $594.84 | $52.72 |
| P/E Ratio | ★ N/A | $63.19 |
| Revenue Growth | N/A | ★ 126.34 |
| 52 Week Low | $8.91 | $33.05 |
| 52 Week High | $30.33 | $213.80 |
Technical Indicators
Market Signals| Indicator | ROIV | CRDO |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 47.85 |
| Support Level | $26.45 | $90.42 |
| Resistance Level | $27.94 | $104.35 |
| Average True Range (ATR) | 0.96 | 6.09 |
| MACD | -0.09 | 0.89 |
| Stochastic Oscillator | 58.64 | 71.07 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.